West Pharmaceutical Services, Inc. WST
390.30 USD -6.39 (-1.61%)
Regular-session close
390.30 0.00 0.00%
After hours · Nov 20, 6:16 PM ET
389.75 Day range 400.90
230.95 52-week range 417.80
- YTD
- +41.86%
- 1 year
- +51.41%
News
seekingalpha.com My Top Dividend Growth Picks In Each GICS Sector (November 2026) I present my top dividend growth picks in each GICS sector based on quality scores. The sector winners would have returned 144% over five years, versus SPY's 63%. Royal Gold is my standout value…
zacks.com Reasons to Add West Pharmaceutical Stock to Your Portfolio Now West Pharmaceutical's growth prospects are fueled by strong HVP demand, expanding biologics exposure and regulatory upgrades, despite near-term headwinds.
seekingalpha.com West Pharmaceutical Services, Inc. (WST) Presents at Jefferies Global Healthcare Conference 2026 Transcript West Pharmaceutical Services, Inc. (WST) Presents at Jefferies Global Healthcare Conference 2026 Transcript
seekingalpha.com Artisan Global Discovery Fund Q3 2026 Portfolio Activity During the quarter, we initiated new positions in Manhattan Associates, Okta and Clean Harbors. In addition to Twilio, West Pharmaceutical and RBC Bearings, we added to Neptune Insurance, Lattice…
defenseworld.net West Pharmaceutical Services, Inc. $WST Position Increased by Eurizon Capital SGR S.p.A. Eurizon Capital SGR S.p.A. boosted its holdings in shares of West Pharmaceutical Services, Inc. (NYSE: WST) by 35.8% during the undefined quarter, according to its most recent 13F filing with the…benzinga.com Citigroup Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $494 Citigroup analyst Joanne Wuensch maintains West Pharmaceutical Servs (NYSE:WST) with a Buy and raises the price target from $412 to $494.
benzinga.com TD Cowen Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $500 TD Cowen analyst Brendan Smith maintains West Pharmaceutical Servs (NYSE:WST) with a Buy and raises the price target from $420 to $500.
benzinga.com Barclays Maintains Overweight on West Pharmaceutical Servs, Raises Price Target to $500 Barclays analyst Luke Sergott maintains West Pharmaceutical Servs (NYSE:WST) with a Overweight and raises the price target from $440 to $500.
benzinga.com Evercore ISI Group Maintains Outperform on West Pharmaceutical Servs, Raises Price Target to $480 Evercore ISI Group analyst Daniel Markowitz maintains West Pharmaceutical Servs (NYSE:WST) with a Outperform and raises the price target from $440 to $480.
benzinga.com West Pharmaceutical Servs Q3 2026 Earnings Call Transcript West Pharmaceutical Servs (NYSE:WST) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…benzinga.com West Pharmaceutical Servs Sees Q4 Adj EPS $2.22-$2.32 vs $2.27 Est; Sees Sales $820.000M-$830.000M vs $826.736M Est West Pharmaceutical Servs (NYSE:WST) is looking for Q4 Adj EPS of $2.22-$2.32 vs $2.27 analyst estimate. sees sales of $820.000 million-$830.000 million vs $826.736 million analyst estimate.
benzinga.com West Pharmaceutical Servs Q3 Adj. EPS $2.66 Beats $2.19 Estimate, Sales $874.500M Beat $825.700M Estimate West Pharmaceutical Servs (NYSE:WST) reported quarterly earnings of $2.66 per share which beat the analyst consensus estimate of $2.19 by 21.46 percent. This is a 35.71 percent increase over earnings…
benzinga.com West Pharmaceutical Servs Raises FY2026 GAAP EPS Guidance from $9.01-$9.26 to $9.31-$9.41 vs $8.47 Est West Pharmaceutical Servs (NYSE:WST) raises FY2026 GAAP EPS guidance from $9.01-$9.26 to $9.31-$9.41 vs $8.47 analyst estimate..
